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Abstract
Infection of swine with virulent porcine reproductive and respiratory syndrome (PRRS) virus induced a rapid, robust antibody response
that comprised predominantly nonneutralizing antibodies and waned after approximately 3 months. In contrast, the initial onset of
virus-specific interferon (IFN)--secreting cells (SC) in the pig lymphocyte population remained at a fairly low level during this period and
then increased gradually in frequency, plateauing at 6 months postinfection. A similar polarization of the host humoral and cellular immune
responses was also observed in pigs immunized with a PRRS-modified live virus (MLV) vaccine. Even coadministration of an adjuvant that
enhanced the immune response to a pseudorabies (PR) MLV vaccine failed to alter the induction of PRRS virus-specific IFN- SC
(comprising predominately CD4/CD8 double positive memory T cells with a minority being typical CD4/CD8 T cells) and the
generation of neutralizing antibodies. Moreover, unlike inactivated PR virus, nonviable PRRS virus did not elicit virus-neutralizing antibody
production. Presumably, an intrinsic property of this pathogen delays the development of the host IFN- response and preferentially
stimulates the synthesis of antibodies incapable of neutralization.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Porcine reproductive and respiratory syndrome (PRRS)
is currently considered to be the most significant and eco-
nomically important infectious disease to afflict swine
worldwide. The causative agent, PRRS virus, was first iso-
lated in The Netherlands in 1991 (Wensvoort et al., 1991)
and then a year later in the United States (Collins et al.,
1992). This pathogen is a member of the Arteriviridae, a
family of small, cytolytic, positive-stranded, enveloped
RNA viruses (Benfield et al., 1992; Wensvoort, 1993) in the
order Nidovirales (Cavanagh, 1997; Conzelmann et al.,
1993; Meulenberg et al., 1993; Pringle, 1996). Other mem-
bers of this family are equine arteritis virus, lactate dehy-
drogenase-elevating virus (LDV) of mice, and simian hem-
orrhagic fever virus (Conzelmann et al., 1993; Meulenberg
et al., 1993; Plagemann and Moennig, 1992). A common
biological property of these viruses is their primary repli-
cation in host alveolar macrophages (Wensvoort et al.,
1991) and some cells of the monocyte lineage (Pol and
Wagenaar, 1992; Voicu et al., 1994), from where they may
influence the host immune response. Additionally, PRRS
virus can localize in various organ systems (Mengeling et
al., 1995, 1996; Rossow et al., 1995; Shibata et al., 1997)
and produce persistent infections in the absence of viremia
(Allende et al., 2000; Van Reeth, 1997; Wills et al., 1997).
Although both clinical and basic research have increased
our knowledge about the biology and pathogenesis of the
PRRS virus, still little is known about its immunobiology or
which components of the porcine immune response may be
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important in establishing protective immunity against this
pathogen. An important characteristic of the immunity elic-
ited against PRRS virus is an abundant antibody response
that exhibits minimal virus neutralizing (VN) activity (Al-
bina et al., 1998b; Gonin et al., 1999; Nelson et al., 1994;
Loemba et al., 1996; Vezina et al., 1996; Yoon et al., 1996).
This inadequate production of VN antibody, in combination
with the known ability of PRRS virus to produce a persis-
tent infection, lasting up to 150 days (Allende et al., 2000),
indicates a potential reliance by the host on cell-mediated
immunity to protect itself against this microbe. Although
limited studies have focused on this area, it has been dem-
onstrated that infected pigs do develop a transient T-cell-
mediated PRRS virus-specific lymphoproliferative re-
sponse, starting at 4 weeks postinfection and lasting an
additional 9 (Bautista and Molitor, 1997) to 14 weeks
(Lopez-Fuertes et al., 1999). Targets of this response have
been identified as the viral matrix protein and the envelope
glycoprotein GP5 (Bautista et al., 1999). Moreover, immu-
nization of pigs with a plasmid encoding GP5 has been
shown to stimulate a lymphoproliferative response and pro-
vide some protection against challenge with virulent virus
(Pirzadeh and Dea, 1998). Infected pigs also exhibit a de-
layed-type hypersensitivity response to PRRS virus (Bau-
tista and Molitor, 1997), although the importance of this
response in regard to protection is not known.
Since host interferon (IFN)- production is the major
protective mechanism against infections by a variety of
cytopathic viruses (Ramsay et al., 1993; Zinkernagel et al.,
1996), it is likely that this cytokine plays a role in protection
against PRRS virus in pigs. In this regard, IFN-mRNA has
been detected in the lymph nodes, lungs (Rowland et al.,
2001), and peripheral blood mononuclear cells (PBMCs)
(Lopez-Fuertes et al., 1999) of PRRS virus-infected pigs.
Moreover, through the use of cultured cells, porcine IFN-
has been shown to block PRRS virus replication (Bautista
and Molitor, 1999), apparently by the inhibition of viral
RNA synthesis via a dsRNA inducible protein kinase (Row-
land et al., 2001).
Despite this intriguing evidence supporting a primary
role for a virus-specific IFN- response in porcine immunity
against PRRS virus infection, a thorough analysis of this
possibility has yet to be undertaken. We have now applied
a sensitive and quantitative ELISPOT assay that enables
enumeration of virus-specific IFN- secreting cells (SC)
(Zuckermann et al., 1998) to examine the kinetics and
magnitude of the IFN- response of pigs to exposure to
virulent, attenuated, or inactivated PRRS virus. Simulta-
neously, we also conducted a temporal determination of the
appearance and retention of both neutralizing and nonneu-
tralizing anti-PRRS virus antibodies. For comparison, the
effects of vaccination with a proven strong stimulator of
both humoral (VN antibody) and cell-mediated (IFN- SC)
porcine immunity, namely a pseudorabies (PR) modified
live virus (MLV) vaccine (Zuckermann et al., 1999), were
also monitored. Based on the results of these studies, we
conclude that PRRS virus induces not only a poor VN
antibody response but also a weak T-cell-mediated IFN-
response that increases gradually in magnitude over a period
of months. Moreover, the degree of PRRS virus virulence
does not appear to influence the tardiness of this response.
Results
Duration of viremia in pigs infected with wild-type
PRRS virus
To examine the kinetics of the development of the im-
mune response to virulent PRRS virus, a group of 8-week-
old piglets was intranasally inoculated with the field strain
12068-96. The success of the experimental infection was
evidenced by the presence of viremia that could still be
detected at 2 weeks postinfection (Table 1). Although at this
point viable PRRS virus could be isolated from the blood of
only three of the four infected pigs, the presence of virus in
the serum of all four pigs was evident based on positive
RT-PCR results. In contrast, neither of the two uninfected
pigs exhibited viremia.
Humoral immune response to infection with wild-type
PRRS virus
A specific antibody response to PRRS virus was detected
in the serum of all four pigs within 2 weeks after being
inoculated (Fig. 1A). The amount of these antibodies in-
creased until peaking at approximately 9 weeks later, and
then declined to borderline positive levels by 28 weeks
Table 1
Detection of PRRS viremia
Status Time postinfection (weeks)
1 2 3 4 5 6 7 8 9 10 11 12 13
Infecteda 4/3b 4/3 3/ / / / / / / / c  
Uninfectedd / / / / / / / / / /   
a Four pigs were intranasally infected with 105 TCID50 of virulent PRRS virus strain 12068-96.
b Left designation indicates number of pigs considered to be viremic based on positive RT/PCR result, while the right designation represents the number
of pigs considered to be viremic based on successful virus isolation.
c Only RT/PCR was performed.
d Two pigs were mock-infected with sterile saline.
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postinfection. At this point one of the pigs was considered
to be seronegative since the standard-to-positive (S/P) ratio
of its serum in the ELISA test for PRRS virus was less than
the established cut-off value of 0.4. As expected, uninfected
animals maintained an S/P ratio below 0.4 throughout the
study. Unlike the overall rapid production of anti-PRRS
virus antibodies reactive in an ELISA assay, VN antibodies
against this virus were not detected until 11 weeks postin-
fection, and then in only two of the four infected animals
(Fig. 1A). Maximum titers of 1:16 and 1:4, respectively,
were observed 9 weeks later and then declined such that at
34 weeks postinfection one of the two pigs was deemed to
be seronegative.
Cell-mediated immune response to infection with
wild-type virus
In contrast to anti-PRRS virus antibody formation, the
development of cell-mediated immunity as measured by the
frequency of PRRS virus-specific IFN--SC in the pig
PBMC populations was not detected until the third week
postinfection (Fig. 1B). At this time and during the ensuing
10 weeks these values varied approximately twofold within
a range of 50–100 IFN--SC/106 PBMCs. Afterward, the
frequency of PRRS virus-specific IFN--SC cells began to
increase and reached an average of 266  35 cells/106
PBMC at 34 weeks postinfection. At termination of the
Fig. 1. Kinetics of the humoral and cellular immune responses of pigs to infection with virulent PRRS virus. Groups of pigs were inoculated intranasally with
PRRS virus strain 12068-96 or mock-treated with sterile saline. At the indicated times after infection serum and PBMCs were obtained from their peripheral
blood. For humoral immunity (A), results are expressed as S/P ratios measured by ELISA or as the log2 of the reciprocal of the largest dilution of serum
that inhibited the development of a virus-induced cytopathic effect in cell culture (VN titer). S/P ratios 0.4 and VN titers 2 (log2) are considered to be
negative. For cellular immunity (B), the frequency of PRRS virus-specific IFN--SC/106 PBMCs in each sample was determined by using an ELISPOT assay.
Each value represents the mean response of four (infected) or two (uninfected) pigs  standard error of the mean (SEM).
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experiment (48 weeks postinfection) the relative percentage
of IFN--SC was further enhanced to 394  45 cells/106
PBMC (data not shown). A similar, relatively high fre-
quency of PRRS virus-specific IFN--SC (527  49 cells/
106 PBMCs) was observed in the blood from 11 boars at 45
weeks after infection with the same strain of PRRS virus.
When 4 of these boars were tested 53 weeks later, the
average frequency of PRRS virus-specific IFN- SC was
still 450  50 cells/106 PBMC. Thus, the host IFN- re-
sponse to infection with virulent PRRS virus can be char-
acterized as being prolonged in regard to its establishment
and being relatively stable once established.
Comparison of the IFN- response to immunization with
either PRRS or PR modified live virus vaccines
In comparison to that reported for PR virus (Zuckermann
et al., 1999), the intensity of the porcine IFN- response to
infection with virulent PRRS virus appeared to be weak
during the 13 weeks immediately following inoculation. To
determine if a similar phenomenon occurred with attenuated
PRRS virus, the cell-mediated immune responses of age-
matched pigs to immunization with either a PRRS or a PR
MLV vaccine were monitored (Table 2). By 3 weeks after
vaccination with PR virus, the respective animals had de-
veloped a group mean frequency of 289  82 virus-specific
IFN--SC/106 PBMCs. In contrast, pigs receiving the PRRS
virus vaccine generated a significantly (P  0.05) lower
number of virus-specific IFN--SC (82  25 cells/106
PBMCs). Even when the dosage of antigen used as stimulus
in the ELISPOT assay was reduced 10-fold, the same rela-
tive difference in the frequencies of virus specific IFN--SC
was apparent. Since neither group of pigs had IFN--SC
that recognized the reciprocal virus, the specificity of both
the immune response and the assay was verified. To further
examine this difference in the intensity of the cellular im-
mune response, both groups of animals were boosted with
the respective original type of vaccine. Although at 2 weeks
after this booster immunization the frequencies of both PR
and PRRS virus-specific IFN--SC doubled to 587  105
and 164  60 IFN--SC/106 PBMCs, respectively, the
IFN- response to PRRS virus remained significantly lower
than the response to PR. Once again, a 10-fold reduction in
the amount of viral stimulus used in the assay did not alter
the relative difference in the extent of the IFN- response to
the two viruses. Thus, the intensity of the short-term virus-
specific IFN- response of swine to either a primary or a
booster immunization with a PRRS MLV vaccine was
lower than that to its PR virus counterpart.
Effect of coadministration of a conventional adjuvant on
the porcine immune response to vaccination with either
PRSS or PR modified live virus vaccine
Because of the observed relatively weak cellular immune
response to exposure to the PRRS MLV vaccine, enhance-
ment of this immunity was attempted by coadministration of
an adjuvant. This approach was considered because inclu-
sion of the commercial adjuvant Imugen was previously
found to intensify the IFN- response to a PR MLV vaccine
(Zuckermann and Martin, unpublished observations). Ac-
cordingly, pigs were injected intramuscularly with either a
PRSS or a PR MLV vaccine alone or in combination with
this adjuvant. Control animals received either adjuvant
alone, a commercial inactivated PRRS virus (already for-
mulated with an adjuvant) or a BEI-inactivated PR virus
mixed with Imugen. All pigs were boosted with the same
respective vaccine formulation 3 weeks later. Just prior to
the second immunization, the number of PR virus-specific
IFN--SC in the blood of animals receiving the PR MLV
vaccine mixed with adjuvant (366  80 cells/106 PBMCs)
was approximately 2.5-fold greater than that in the blood of
pigs vaccinated with PR MLV alone (148  21/106
PBMCs) (Fig. 2B). Likewise, enhancements of approxi-
mately 1.8-fold (730  68 vs 400  46 cells/106 PBMCs)
and 1.4-fold (584  57 vs 421  46 cells/106 PBMCs) at 1
and 2 weeks after the booster vaccination, respectively,
were also found to be associated with the inclusion of
adjuvant during PR immunization. In contrast, the addition
of the same adjuvant to the PRRS MLV failed to enhance
the IFN- response to this virus even after a booster immu-
nization (Fig. 2A). For instance, the virus-specific IFN-
-SC frequency in the blood of pigs at 1 week after the
second immunization with PRRS MLV given in the pres-
ence or absence of adjuvant was 113  21/106 PBMCs and
120  37 cells/106 PBMCs; respectively. Moreover, as
observed in the first comparative study (Table 2), the cell-
mediated immune response to the PRRS virus was consis-
tently lower than that to the PR MLV. Apparently, both
Table 2
Intensity and specificity of the host IFN- response to immunization
with either porcine reproductive and respiratory syndrome (PRRS) or
pseudorabies (PR) MLV vaccine
Immunizationb MLV vaccine Challenge antigen (ELISPOT)a
Dose (MOI) PRSS virus PR virus
Primary PRRS 1.0 82  25c 2  1
0.1 33  25d 1  1
PR 1.0 3  1 289  82c
0.1 2  1 164  65d
Secondary PRRS 1.0 164  60e 20  8
0.1 45  14f 4  1
PR 1.0 3  1 587  105e
0.1 4  2 362  85f
a Results are presented as the number of IFN--SC detected per 106
PBMC isolated from MLV-vaccinated pigs by an ELISPOT assay after a
20-h exposure of the lymphocytes to the indicated amount of virus.
b PBMCs were isolated from the pigs either at 3 weeks after primary
vaccination or 2 weeks after secondary vaccination (5 weeks after primary
immunization) with MLV.
c Difference between the two values is significant (P  0.05).
d Difference between the two values is significant (P  0.05).
e Difference between the two values is significant (P  0.03).
f Difference between the two values is significant (P  0.05).
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viruses must be viable to elicit the generation of virus-
specific IFN--SC, since these entities were not detected in
pigs receiving either a commercial inactivated PRRS virus
vaccine or BEI-inactivated PR virus (Figs. 2A and B).
Despite the inability of inactivated PR virus to elicit a
detectable cell-mediated immune response, it still readily
induced a humoral immune response as evidenced by the
production of VN antibodies at a level similar to that gen-
erated after PR MLV immunization (Fig. 3B). In contrast, a
significant VN titer was not obtained in pigs receiving either
the live or inactivated PRRS virus vaccine (Fig. 3A). More-
over, even the addition of adjuvant had no stimulatory effect
on the ability of the PRRS MLV to elicit production of VN
antibodies, although there was an approximately threefold
enhancement (P  0.05) of VN titer in the presence of this
agent when the PR MLV vaccine was used (Fig. 3B).
Polarization of the humoral and cell-mediated immune
responses of swine to vaccination with
PRRS MLV vaccine
To ascertain if the host IFN- response to attenuated
PRRS virus developed with kinetics similar to that observed
in pigs infected with virulent PRRS virus (Fig. 1), the period
for determining the frequency of virus-specific IFN--SC in
pigs vaccinated twice with PRRS MLV was extended past
the 2-week postbooster time frame used in the initial study
(Fig. 4A). In these animals the cell-mediated immune re-
sponse varied approximately twofold within a range of
50–100 PRRS virus-specific IFN--SC/106 PBMC during
the 1 week preceding and the 6 weeks following the second
immunization. Thus, no immediate effect of a boosting
vaccination on the host INF- response was apparent. How-
ever, by 18 weeks after the second vaccination, the fre-
quency of IFN--SC had increased to 220  10 cells/106
PBMCs, had reached a value of 443  38 cells/106 PBMC
14 weeks later, and was even greater at 51 weeks postvac-
cination (641  24 cells/106 PBMCs; data not shown).
Remarkably, as seen in the pigs infected with wild-type
PRRS virus, the kinetics of the host humoral immune re-
sponse to the PRRS MLV (Fig. 4B) was the opposite of that
of the IFN- response. There was a rapid production of
anti-PRRS virus antibodies between 2 and 4 weeks post
primary vaccination. Afterward, their quantity steadily de-
clined and by 32 weeks after primary vaccination these
Fig. 2. Comparison of the intensities of the PRRS and PR virus-specific IFN- responses of pigs to vaccination either with live virus in the presence or absence
of adjuvant or with inactivated virus. Groups of pigs were immunized either with an unmodified, commercially available PRRS (A) or PR (B) MLV vaccine
or with the respective vaccines that had first been mixed with the oil-in-water adjuvant Imugen and received a booster of the same formulation 3 weeks later.
Additional groups of pigs were immunized either with an inactivated PRRS virus vaccine (A) or BEI-treated PR virus (B) or mock-vaccinated with sterile
saline (A, B) and were also boosted 3 weeks later. PBMCs were isolated from the pigs at the indicated times postimmunization and the frequency of PRRS
(A) or PR (B) virus-specific IFN--SC was determined by using an IFN- ELISPOT assay. Significant differences between the quantities of virus-specific
IFN--SC detected in the blood of animals immunized with PRRS MLV in the presence or absence of adjuvant versus those receiving the inactivated PRRS
virus vaccine (A) are represented by an asterisk (P  0.05). Likewise, significant differences between the quantities of virus-specific IFN--SC detected in
the blood of animals receiving PR MLV in the presence of adjuvant versus those receiving PR MLV in the absence of adjuvant or BEI-treated PR virus (B)
are represented by an asterisk (P  0.01) and a double asterisk (P  0.001), respectively. These statistical determinations were obtained by using the FPLSD
test. Each value represents the mean response of five pigs  SEM.
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antibodies could hardly be detected by using an ELISA
assay. Presumably, the initial, intense humoral immune re-
sponse was due to the presence of nonneutralizing antibod-
ies, since only half of the animals had a detectable level of
VN antibodies. Moreover, their peak average titer of 2.6
log2 occurred at 14 weeks post primary vaccination—10
weeks after the maximum amount of anti-PRRS virus anti-
body was detected by ELISA in the serum of vaccinated
pigs.
Phenotypic analysis of PRRS virus-specific
IFN--secreting cells
To establish the phenotype of the IFN--SC, antibody-
directed, complement-mediated depletion studies were per-
formed with PBMCs isolated from pigs previously vacci-
nated twice against PRRS virus (Fig. 5). Ninety percent of
the PRRS virus specific IFN--SC were eliminated as a
result of exposure to anti-porcine CD3 mAb. Likewise,
incubation with mAbs reacting with either porcine CD4 or
CD8 caused 95 and 96%, respectively, of these cells to be
depleted. In contrast, treatment with anti-CD8 antibodies
resulted in the elimination of less than 18% of the IFN--SC
population. Since exposure to antibody recognizing the por-
cine B-cell marker CD21 had a minimal reductive effect
(1% depletion), PRRS virus-specific IFN--SC appear to be
predominately CD3 T cells that express both CD4 and
CD8, i.e., CD4/CD8 double positive (DP) T cells, with
most of the remainder expressing CD8. The later popula-
tion represents the classical CD4/CD8 cytotoxic T-
cell population (Zuckermann et al., 1990). In general, these
two T-cell subsets may be responsible for the host IFN-
response to virus invaders, since similar results were ob-
tained in depletion studies conducted with PBMCs originat-
ing from PR virus-immune pigs (data not shown).
Discussion
In the present study a remarkable temporal polarization
of the host cellular and humoral immune responses to in-
fection by either virulent or attenuated PRRS virus was
observed. From its onset at 2–3 weeks postinfection and
during the ensuing 10–12 weeks, the IFN- response was
relatively weak and then its intensity began to increase
gradually. In contrast, anti-PRRS virus antibodies incapable
of neutralizing this virus were abundant until near the end of
this period, when their numbers were dwindling. Coincident
with their decline was the appearance of VN antibodies—a
phenomenon previously observed during PRRS virus infec-
tion of swine (Albina et al., 1998b; Molitor et al., 1997;
Nelson et al., 1994; Shibata et al., 2000). Interestingly,
temporal segregation of the humoral response is actually
directed against two epitopes on the same protein, as indi-
cated by the appearance of neutralizing antibodies recog-
nizing PRRS virus glycoprotein 5 as the level of antibodies
reacting with an immunodominant nonneutralizing determi-
nant in this protein declined (Ostrowski et al., 2002). Pre-
sumably, this two-step humoral immune response may
actually contribute to the continuance of PRRS virus repli-
cation (Wills et al., 1997), possibly via antibody dependent
enhancement (ADE) of infection (Yoon et al., 1996). If so,
Fig. 3. Comparison of the intensities of the PRRS and PR virus-specific humoral immune responses of pigs to vaccination either with live virus in the presence
or absence of adjuvant or with inactivated virus. Groups of pigs were immunized either with an unmodified, commercially available PRRS (A) or PR (B)
MLV vaccine or with the respective vaccines that had first been mixed with the oil-in-water adjuvant Imugen and received a booster of the same formulation
3 weeks later. Additional groups of pigs were immunized either with an inactivated PRRS virus vaccine (A) or BEI-treated PR virus (B) or mock-vaccinated
with sterile saline (A, B) and were boosted 3 weeks later. Sera were obtained from the pigs at the indicated times postimmunization and the titer of PRRS
(A) and PR (B) VN antibody in the blood of these animals was determined by a VN test. Results are expressed as the reciprocal of the highest dilution of
serum that inhibited the development of a virus-induced cytopathic effect in cell culture. VN titers 2 (log2) are considered to be positive. A significant
difference between the quantity of VN antibodies detected in the blood of animals immunized with PR MLV in the presence or absence of adjuvant (B) is
represented by an asterisk (P  0.05). These statistical determinations were obtained by using the FPLSD test. Each value represents the mean response of
five pigs  SEM.
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then the initial onslaught of non-neutralizing anti-PRRS
virus antibodies may represent a major impairment to the
development of vaccine-induced protective immunity. A
similar scenario has been found when examining the host
response to human immunodeficiency virus (HIV). In this
case within 2 months postinfection, most patients develop
anti-HIV antibodies that can be detected by using ELISA or
Western blot methodology. However, the titer of VN anti-
bodies against the autologous isolate is fairly low or unde-
tectable. Although neutralizing antibodies against T-cell
line-adapted variants of HIV-1 are produced, at least
25–53 weeks pass before high titers against these strains
are observed (Pilgrim et al., 1997). Because of this situation,
the presence of enhancing antibodies against HIV and their
potential harmful effects in volunteers immunized with
HIV-1 candidate vaccines have been considered to be a
major hindrance in the provision of immunity to this virus
(Fust, 1997). Thus, both PRRS virus and HIV may possess
a similar strategy for evading the potentially inhibitory
activity of the host humoral immune response and present a
similar challenge to effective vaccination.
That VN antibodies are protective against subsequent
PRRS virus infections has been established (Osorio et al.,
2002). Sows having acquired a VN antibody titer of 1:16 by
Fig. 4. Kinetics of the humoral and IFN-  response of pigs to immunization with a PRRS MLV vaccine. A group of pigs were immunized with PRRS MLV
vaccine and then were boosted with the same vaccine 3 weeks later. At the indicated times post primary immunization, serum and PBMC were obtained from
their peripheral blood. For cellular immunity (A), the frequency of PRRS virus-specific IFN--SC/106 PBMCs in each sample was determined by using an
ELISPOT assay. For humoral immunity (B), results are expressed as S/P ratios measured by using ELISA or as the log2 of the reciprocal of the largest dilution
of serum that inhibited the development of a virus-induced cytopathic effect in cell culture (VN titer). S/P ratios 0.4 and VN titers 2 (log2) are considered
to be negative. Values up to and including 9 weeks represent the mean response of 35 pigs SEM. From 10 to 23 weeks, values represent the mean response
of 12 pigs  SEM and thereafter values represent the mean response of 6 pigs  SEM.
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passive immunity could clear a PRRS virus infection when
challenged at 90 days gestation and not experience repro-
ductive failure (abortion). Unfortunately, as observed in the
present study, the production of VN antibodies by pigs
vaccinated (Mengeling et al., 1999) or infected (Gonin et
al., 1999; Nelson et al., 1994; Shibata et al., 2000; Vezina et
al., 1996) with PRRS virus is limited (titers are usually
1:8) and sporadic. Even our attempt to enhance the ability
of a PRRS MLV vaccine to elicit VN activity by including
an adjuvant in the vaccine formulation failed, despite the
fact that the inclusion of the same adjuvant significantly
increased the titer of VN antibodies generated in response to
immunization with the PR MLV vaccine. Experimentally, a
high titer of PRRS VN antibodies has been obtained in pigs
but only after hyperimmunization consisting of sequential
injections of wild-type virus mixed with Freund’s adjuvant
(Nelson et al., 1994; Osorio et al., 2002; Ostrowski et al.,
2002). Clearly, the need to undergo such an intensive im-
munization regime indicates that a dominant and very ef-
fective mechanism normally prevents the creation of a
strong VN antibody response against PRRS virus. The
cause of this prevention is currently unknown, although the
presence of decoy immunodominant epitopes is likely re-
sponsible (Ostrowski et al., 2002). A similar situation has
been observed in the case of HIV, where antibodies against
a neutralizing epitope in gp120 are not detected until several
months after infection. Instead, antibodies against nonneu-
tralizing epitopes in this protein are produced during the
first 6 months following infection (Ho et al., 1991). Thus, it
appears that PRRS virus, like HIV, delays the induction of
neutralizing antibody formation by focusing the immune
response to nonneutralizing epitopes on an immunodomi-
nant viral protein (Ostrowski et al., 2002).
Despite the limited humoral immune response to PRRS
virus vaccination, pigs do efficiently clear subsequent ho-
mologous virus infections (van Wonesel et al., 1998). In
fact, PRRS virus-infected pigs lacking detectable amounts
of VN antibodies can apparently still eliminate this patho-
gen (Labarque et al., 2000). Presumably this ability is at
least partially dependent on induced cell-mediated immu-
nity, especially the host IFN- response.
In this regard, mRNA encoding IFN-, a cytokine known
to inhibit PRRS virus replication (Bautista and Molitor,
1999; Rowland et al., 2001), has been detected in the lung
and lymphoid tissues of PRRS virus-infected pigs (Lopez
Fuertes et al., 1999; Rowland et al., 2001). Additional in-
direct evidence suggesting a role for IFN- in mediating
protective immunity against PRRS virus includes (i) the
demonstration that pigs which have recovered from a pre-
vious PRRS virus infection are at least partially resistant to
a secondary challenge by the homologous virus strain for up
to 604 days after the initial infection (Lager et al., 1997)—a
time as shown in the present study when there was still a
strong presence of PRRS virus-specific IFN--SC (450 
50 cells/106 PBMCs) but not of VN antibodies; (ii) the
obtainment of a positive correlation coefficient of 0.61 (P
0.0013) between the frequency of PRRS virus-specific IFN-
-SC in the lymphocyte population of previously MLV-
immunized sows at the time of virulent PRRS virus chal-
lenge (90 days of gestation) and the number of subsequent
live-born piglets (unpublished observations); and (iii) the
observation that of the routinely vaccinated sows at a com-
mercial facility, only those with a frequency of150 PRRS
virus-specific IFN--SC/106 PBMCs did not abort as a
result of exposure to a natural outbreak of PRRS during
their pregnancies (unpublished observations).
Although the number of virus-responsive, cytokine-se-
creting cells may be underestimated by using the ELISPOT
(Waldrop et al., 1997), the comparative approach used in the
current study demonstrated that the initial cell-mediated
immune response as defined by the frequency of virus-
specific IFN--SC was substantially lower to PRRS virus
than to PR virus. In addition, the gradual increase in the
frequency of PRRS-virus-specific IFN--SC in the periph-
eral blood of swine during an interval of 16 to 24 weeks
after infection or vaccination confirmed that the initial
IFN- response was weak. The kinetics of this response is
unlike the situation in humans and mice, where the fre-
quency of CD4 T cells specific for other viruses is usually
either fairly constant (Flan˜o et al., 2001; Rentenaar et al.,
2000; Waldrop et al., 1997) or decreasing (Homann et al.,
2001) during the several months ensuing infection. One
exception is the observed progressive increase in the fre-
quency of Sendai virus-specific CD4 T cells in mice dur-
ing the first 6 months postinfection (Topham and Doherty,
Fig. 5. Phenotypic characterization of PRRS virus-specific IFN--SC.
PBMCs from PRRS virus-immune pigs were incubated in the presence of
one of the indicated anti-porcine CD mAbs or left untreated. After expo-
sure to complement, the number of PRRS virus-specific IFN--SC present
in the unlysed cell populations was determined by using an ELISPOT
assay. Results are shown as the percentage depletion, calculated using the
formula 100  [100 (number of spots in antibody  complement-treated
well)/number of spots in complement only-treated well]. Data presented
represent the average of six independent experiments performed with
PBMC from four different pigs.
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1998). In this case the expansion was partially attributed to
an accumulation of memory cells as the host aged. Such an
explanation is not applicable to the present situation, be-
cause swine peripheral blood T cells exhibiting a memory
phenotype are not readily detected until the animals are12
months old (Zuckermann and Husmann, 1996) and the pigs
used in the present study were terminated by, at most, 9
months of age. A second variance is the observed late
emergence (1 month) of mouse CD4 cytotoxic T cells in
response to infection by Mycobacterium tuberculosis (Orme
et al., 1992). This delay was proposed to be the result of
clonal expansion and an apparent change in the function of
previously generated, cytokine (IL-2)-secreting protective
CD4 cells (Orme et al., 1993).
A mechanism, similar to that proposed for the impedance
of mouse anti-M. tuberculosis cell-mediated immunity,
could be operative in regard to the protracted generation of
anti-PRRS virus IFN--SC in swine. Thus, a lag in the
transition of virus-specific T cells into a predominate pop-
ulation capable of secreting IFN--SC upon interaction with
PRRS virus, and not functional inactivation of the T cells,
would be responsible. That there are abundant amounts of
active T cells in the host early after PRRS virus infection or
vaccination is indicated by the differentiation of B cells into
ones secreting characteristic immunoglobulins of the G and
A isotypes. Without substantial T-cell involvement with
virus-specific B cells in the lymphoid tissues, the robust
virus-specific humoral immune response detected in both
serum and bronchoalveolar lavage fluids by 3 weeks postin-
fection (Labarque et al., 2000) would not be apparent. That
activated T cells can undergo a functional change is sup-
ported by the observation that the frequency of PRRS virus-
specific IFN--SC can be increased twofold by culturing
PBMCs with viral antigen in the presence of exogenous
IL-12 (unpublished observations). Clearly, direct visualiza-
tion of PRRS virus-specific T cells with MHC class I or
class II tetramers would be necessary for the precise mea-
surement of the frequency of virus-specific T cells, regard-
less of their cytokine expression profile. Alternatively, the
use of ELISPOT assays designed to recognize other cyto-
kines such as IL-2, IL-4, or IL-10 would allow for the
enumeration of virus-specific T cells presumed to perform
other functions. Likewise, the possibility that sequestration
of virus-specific T cells into tissues prevents the rapid in-
duction of the generation of IFN--SC is also not plausible.
Such isolation events are not compatible with the demon-
strated availability of a relatively strong PRRS virus-spe-
cific lymphoproliferative response in the peripheral blood of
pigs by 4 weeks post PRRS virus infection (Bautista and
Molitor, 1997; Lopez Fuertes et al., 1999). Thus, we hy-
pothesize that exposure to either virulent or attenuated
PRRS virus initially fails to provide an adequate amount of
host-supplied signals necessary for directing the differenti-
ation of a substantial number of virus-specific T cells into
virus-specific IFN--SC.
Generally, the interaction of viruses with the precursors
of dendritic cells (DC) causes them to undergo a maturation
and activation process that renders such cells competent to
secrete cytokines that modulate and direct the differentia-
tion of naı¨ve T cells responding to viral antigens (Banche-
reau and Steinman, 1998; Kadowaki et al., 2000; Steinman,
1991). Of these secreted entities, IFN- is now recognized
as being one that provides a major stimulus for the differ-
entiation of T cells into IFN--SC during a viral infection
(Cella et al., 2000; Cousens et al., 1999; Kadowaki et al.,
2000). Interestingly, PRRS virus has been shown to be
incapable of inducing significant IFN- production by por-
cine alveolar macrophages (Albina et al., 1998a; Buddaert
et al., 1998; Van Reeth et al., 1999) or PBMCs (Albina et
al., 1998a). Thus, a lack of available IFN- during the
development of the primary immunity could be responsible
for the limited, initial IFN- response. In support of this
notion we have observed that providing an exogenous
source of IFN- (unpublished observations) or IL-12 (Mur-
taugh et al., 2002; Foss et al., 2002) at the time of immu-
nization with a PRRS MLV vaccine accelerates the devel-
opment and intensity of a virus-specific IFN- response to
the vaccine. Since, like other viruses, PRRS virus is sus-
ceptible to the anti-viral actions of IFN- (Albina et al.,
1998a), the absence or a very low level of this cytokine
combined with the initially inadequate virus-inhibitory im-
munity could contribute to PRRS virus’s propensity for
prolonged infections and the elicitation of a weak initial
IFN- response. Therefore, a plausible explanation for the
gradual increase of the host IFN- response to PRRS virus
is that IFN- produced by the initially, infrequent virus-
specific IFN--SC could promote, during a period of several
months, the differentiation of additional naı¨ve T cells into
virus-specific IFN--SC. As the frequency of IFN--SC
increased, there would be a microenvironment conducive to
T-cell differentiation into IFN--SC, resulting in an even-
tual enhancement of this type of immune response. In this
regard, a positive feedback loop whereby IFN- stimulates
the expression of the T-box transcription factor, T-bet, that
in turn promotes IFN- production has recently been pos-
tulated (Lighvani et al., 2001).
As to the identity of the porcine IFN--SC, the majority
exhibited a CD3/CD4/CD8 phenotype based on the
results of the antibody and complement-mediated depletions
conducted in the present study. Such CD4/CD8 DP T cells
are usually associated with immune memory function (Sum-
merfield et al., 1996; Zuckermann and Husmann, 1996). In
fact, in swine this cell subset represents the majority of
CD4 memory T cells (Zuckermann, 2000), which have
also been shown to have B-cell helper function (Ober et al.,
1998). In addition to the memory T cells, a second group
composing less than one-fifth of the IFN--SC was identi-
fied as being CD4CD8 T cells which would be ex-
pected to function as cytotoxic T cells. Our demonstration
that the majority of cells secreting IFN- in response to viral
antigens are CD4/CD8 DP extends the results by Rodri-
guez-Carren˜o et al., (2002), who found that porcine cells
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exhibiting this phenotype compose the main population of
IFN--SC PBMCs responding to activation with PMA plus
the calcium ionophore A23187. Moreover, a counterpart to
the swine DP T cell that is found in the peripheral blood of
cynomolgus monkeys (reviewed by Zuckermann, 1999) has
also been show to produce large amounts of IFN- in
response to mitogen or CD3 stimulation (Nam et al., 2000).
Based on the elicitation of IFN- production by CD4/
CD8DP T cells under a variety of conditions as well as the
fact that this type of cell, when isolated from PRRS or PR
virus-immune pigs, is able to secrete IFN- after only a
short exposure (20 h) to its relevant antigen, this lympho-
cyte subset can be considered to be composed of effector
memory T cells. However, confirmation of this classifica-
tion according to the guidelines proposed by Sallusto et al.
(1999) awaits verification of L-selectin (CD62L) and CC-
chemokine receptor 7 (CCR7) expression by these DP cells.
As shown in this study, both virulent and attenuated
forms of PRRS virus are capable of delaying a specific
IFN- response and also of constraining the production of
VN antibodies. In the case of the MLV, this intrinsic ability
was not overcome by the inclusion of a conventional adju-
vant even though the same treatment was very effective at
enhancing the level of virus-inhibitory immunity stimulated
by a PR vaccine virus. Apparently, use of the conventional
adjuvant did not provide the necessary signals to stimulate
the development of cell-mediated immunity against PRRS
virus. Thus, the induction of this type of virus-inhibitory
immunity with the potential to mediate the purging of PRRS
virus from the pig is more problematic than simply increas-
ing the immunogenicity of the vaccine. Rather, it seems
likely that cytokines, i.e., IL-12 or IFN-, produced by cells
of the innate immune system are required to direct the
differentiation of T cells into ones capable of secreting IFN-
upon exposure to PRRS virus. Indeed, as stated above, pro-
viding exogenous sources of either cytokine can enhance and
accelerate the development of IFN--SC, but not VN antibod-
ies (Muratugh et al., 2002; Foss et al., 2002; unpublished
observations). Thus, the influence of PRRS virus on accessory
cell function and antigen presentation as well as regulation of
the host immune response by cytokines must be examined. Our
future efforts will be directed toward determining the molec-
ular basis of how PRRS virus infection or vaccination primar-
ily elicits a nonneutralizing humoral response from the host
and the mechanisms by which the addition of exogenous
agents, namely cytokines, are able to increase the intensity of
the initial IFN- response.
Materials and methods
Viruses and cells
Virulent PRRS virus strain 12068–96 was isolated in
September 1995 from a neonate during an outbreak of the
severe reproductive form of PRRS affecting a breeding farm
located in Johnson County, Nebraska (Sur et al., 1997). The
virulent strain VR-2332 was obtained from ATCC (Hanas-
sas, VA). Quantitation of PRRS virus stocks was performed
in MARC-145 cells and the titers were calculated and ex-
pressed as TCID50/ml (Reed and Muench, 1938). All PRRS
virus stocks used either for intranasal inoculation or as a
source of recall antigen for cellular assays were passaged
three times in MARC-145 cells since isolation from an
animal (strain 12068–96) or retrieval from an ATCC am-
pule (VR-2332). MARC-145 cells were grown in modified
Eagle’s medium (MEM) supplemented with 10% fetal calf
serum, 50 mg/ml gentamicin, 5 g/ml amphotericin B, 110
U/ml penicillin, and 0.2 mg/ml streptomycin (Sigma Chem-
ical Co., St. Louis, MO). The Kaplan (Ka) strain of PR virus
was propagated and titrated in MDBK cells as previously
described (Zuckermann et al., 1990). Both PRRS and PR
virus stocks consisted of virus-infected cell lysates obtained
by freezing and thawing monolayers when they showed
75–80% cytopathic effect. Disrupted cells were centrifuged
at 1000g and 4°C for 15 min and the resulting virus-con-
taining supernatants were stored at 80°C.
Commercially available MLV vaccines for either PRRS
(Ingelvac PRRS MLV, Boehringer Ingelheim Vetmedica,
Inc., St. Joseph, MO) or PR (PrV/Marker Gold, Syntrovet,
Lennexa, KS), as well as an inactivated PRRS virus vaccine
(Promise, Bayer, Shawnee Mission, KS), were used in the
immunization studies. Also included was PR MLV that had
been inactivated by exposure to binary ethylenimine (BEI)
(Bahnemann, 1975; Larghi and Nebel, 1980). For this pur-
pose, 20 ml of reconstituted PrV/Marker Gold (3  105
TCID50/ml) was combined with 2.2 ml of 0.1 M 2-bromo-
ethylamine (Sigma) in 0.2 M NaOH and the resulting solu-
tion was rotated at ambient conditions for 18 h. The reaction
was then terminated by the addition of 0.44 ml of 1 M
sodium thiosulfate. After this treatment the PR virus titer
had been reduced to 10TCID50/ml. The inactivated PR
virus vaccine was mixed with Imugen at a 20% ratio (vol-
ume:volume) prior to injection into pigs.
Animals and housing
For studies involving infection with virulent PRRS virus,
8-week-old Yorkshire  Landrace cross-bred weaned pigs
and 5-month-old boars of the same cross-breed were ob-
tained from an unvaccinated, PRRS and PR virus-free herd
located at the University of Nebraska (Lincoln, NE). For
studies involving immunization with either PRRS or PR
virus vaccines, 8-week-old pigs were acquired from the
PRRS and PR virus-free herd derived from European-bred
pigs obtained originally from Genetiporc (Quebec, Canada)
and currently located at the University of Illinois Veterinary
Swine Research Farm (Urbana, IL). Prior to the beginning
of each study, all pigs were confirmed to be free of PRRS
virus based on the inability to detect either humoral (ELISA
serology; HerdChek PRRS, IDEXX Laboratories, Inc.,
Westbrook, ME) or cellular (IFN ELISPOT) immunity to
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PRRS virus. The PR virus-negative status of the pigs was
also verified by using virus-specific IFN ELISPOT and
VN assays. All animals were maintained in a bio-safety
level 2 facility with temperature and light cycles regulated
to 20°C and 12 h, respectively, and fed a standard corn-
based diet ad libitum.
Animal inoculation with virulent virus
In the first infection study, four 8-week old pigs were
inoculated intranasally with 105 TCID50/2 ml (1 ml per
nostril) of the virulent PRRS virus strain 12068–96. Two
other age-matched pigs remained as uninfected controls. In
a subsequent study involving 11 5-month-old boars, the
dosage was decreased to 103.8 TCID50/2 ml (1 ml per
nostril). In both cases, infected and control pigs were main-
tained in separate isolation rooms. Successful virus infec-
tion of the pigs was confirmed by detecting either viremia
(virus isolation) or PRRS virus genome (RT-PCR) in their
blood.
Animal inoculation with vaccine virus
For the first vaccination study, two groups of 8-week-old
pigs (5 pigs per group) were injected intramuscularly with
either 2 ml of RespPRRS or PrV/Marker Gold MLV and
received a second inoculation of the respective vaccine 3
weeks later. Prior to vaccination and throughout the exper-
iment, each group was maintained in a separate isolation
room. In the second study, 40 8-week-old pigs were ran-
domly assigned into 5-member groups whose housing lo-
cation was based on the type of vaccination protocol being
performed. On one side of the isolation facility were four
units holding pigs immunized intramuscularly with 2 ml of
either RespPRRS MLV alone or supplemented with 20%
(volume:volume) oil-in-water adjuvant Imugen (Intervet,
Inc., Millsboro, DE); Promise inactivated PRRS virus vac-
cine; or sterile saline. On the opposite end were the animal
groups receiving a similar quantity of PrV/Marker Gold
MLV alone or in combination with Imugen, inactivated PR
virus mixed with Imugen, or sterile saline. In a third vac-
cination experiment, aimed at monitoring the short- and
long-term kinetics of the cell-mediated immune response to
PRRS virus, a group of 35 8-week-old pigs were injected
intramuscularly with 2 ml of RespPRRS MLV and received
a second inoculation with the same vaccine 3 weeks later.
The PRRS virus-specific immune response of all 35 pigs
was monitored for 9 weeks. Thereafter, because of logistic
and economic considerations the size of the group was first
reduced to 12 animals and then at 23 weeks post primary
vaccination further decreased to 6 pigs.
Detection of PRRS virus in sera
The presence of infectious PRRS virus in the peripheral
blood of pigs was determined as described by Benfield et
al., (1992). Briefly, twofold serial dilutions of serum in 0.1
ml MEM were added to duplicate MARC-145 monolayers
grown in a 96-well cell culture plate. After 3 days of culture
at 37°C in a 5% CO2 atmosphere, positive scores were
based on the observation of a characteristic cytopathic effect
(Kim et al., 1993). The presence of PRRS virus nucleic acid
in serum and semen was determined by using RT-nested
PCR of extracted RNA (Sur et al., 1997). The outer set of
primers designed to direct the amplification of a 403-bp
fragment of ORF6 of PRRS virus isolate 12068–96 were
AGGTGCTCTTGGCGTTCTCTATT and GCTTTTCTGC-
CACCCAACACG, respectively. Forward and reverse prim-
ers for the nested PCR were CCTCCAGATGCCGTTTGT-
GCT and TGCCGTTGACCGTAGTGGAGC and enabled
the generation of a 150-bp amplicon. Cycling parameters for
both PCRs were: 95°C, 1 min; 60°C, 1 min; 72°C, 1 min in
a standard PCR mix with 4 mM MgCl2 for a total of 30
cycles.
Determination of humoral immunity
To measure the presence of PRRS virus-specific antibod-
ies in swine sera, a commercially available ELISA (Herd-
Chek PRRS) was used. Sample-to-positive (S/P) ratios
greater than 0.4 were considered positive. PRRS virus neu-
tralizing antibody titers were measured using modified flu-
orescent focus neutralization assay as described by Wu et al.
(2001). Briefly, 100 l of twofold serially diluted pig serum
was mixed with an equal volume of homologous PRRS
virus at a concentration of 2000 TCID50/ml, incubated for
1 h at 37°C, and then transferred to a 96-well plate contain-
ing confluent MARC-145 cells. After 24 h, the monolayers
were fixed in 80% acetone and incubated for 1 h with
fluorescein-conjugated anti-PRRS virus monoclonal anti-
body SDOW-17 (Wu et al., 2001), diluted 1:100 in phos-
phate-buffered saline (PBS) containing 5% horse serum.
Cells exhibiting a cytopathic effect were visualized as flu-
orescent masses when viewed with a fluorescent micro-
scope. A standard SN assay was used to assess the PR
virus-specific antibody response in pigs (Zuckermann et al.,
1998). In this assay cytopathic effects were visualized by
light microscopy using an inverted microscope. The end
point titer of the SN of either test was expressed as the log2
of the reciprocal of the highest serum dilution that inhibited
the development of virus-induced cytopathic effect.
Isolation of peripheral blood mononuclear cells
Swine PBMCs were isolated from fresh venous blood
anti-coagulated with 5 mM heparin. Buffy coats containing
PBMCs were collected following centrifugation at 450g and
20°C for 30 min through a Ficoll–Hypaque 1077 (Sigma)
gradient. PBMCs were then washed twice in 15 ml Hanks’
balanced salt solution and suspended in RPMI medium
(Life Technologies, Gaithersburg, MD) supplemented with
2% fetal porcine serum (Life Technologies), 100 U/ml pen-
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icillin (Sigma), 100 g/ml streptomycin (Sigma), 100 U/ml
gentamicin (Sigma), 4 mM L-glutamine (Sigma), 1 mM
sodium pyruvate (Life Technologies), 1 MEM nonessen-
tial amino acids (Life Technologies), and 250 mM 2-mer-
captoethenol (Sigma).
Antibodies
Purified P2G10 monoclonal antibody (mAb) and biotin-
labeled P2C11 mAb, which are specific for different
epitopes of porcine IFN- (Mateu de Antonio et al., 1998),
were purchased from BD/Pharmingen (San Diego, CA).
Purified mAbs specific for porcine CD3 (8E6), CD4 (74-
12-4), CD8 (76-2-11), CD8 (PG164A), and CD21 (BB6-
11C9) were purchased from VMRD, Inc. (Pullman, WA).
Determination of cell-mediated immunity
The intensity of the cellular immune response was quan-
tified by utilizing an IFN- ELISPOT assay as previously
described (Zuckermann, et al., 1999). Briefly, 96-well Im-
mulon II plates (Dynatech, Inc.) were coated with 50 l per
well of a 10 g/ml solution of mAb P2G10 in 0.1 M
carbonate buffer, pH 9.6. After an overnight incubation at
4°C, each well was washed three times with sterile PBS and
then incubated with 50 l of RPMI supplemented with 5%
fetal porcine serum for 2 h at 37°C in a 5% CO2 atmosphere.
PBMC from virus-infected, vaccinated, or control pigs were
plated at 5  105 viable cells per well. In all samples,
PBMC were 98% viable as confirmed by vital dye exclu-
sion.
The in vitro recall response to PR virus or PRRS virus
was stimulated by the addition of antigen in the form of live
virus corresponding to the respective one used for infection
or vaccination. To perform a valid comparison between the
immune responses elicited by exposure to these two viruses,
the dose of recall viral antigen to be used was titrated to be
suboptimal in regard to stimulation of the PBMCs. For both
viruses, this amount was ascertained to be at a multiplicity
of infection (MOI) of between 0.1 and 1.0.
PBMCs were exposed to viral antigen at 37°C in a 5%
CO2 atmosphere for 20 h. This short incubation time per-
mits a direct determination of the frequency of PRRS virus-
specific INF--SC in each sample, since this interval is not
of sufficient duration for cell replication. Afterward, the
cells were removed by washing the wells six times with
PBS containing 0.05% Tween-20. Fifty microliters of 0.5
g/ml biotin-labeled mAb P2C11 in 0.05% PBS–Tween
was then added to each well and the plates were incubated
for 1 h at 37°C. After washing, 50 l of 0.31 g/ml of
streptavidin–horseradish peroxidase (SA-HRP; Zymed; San
Francisco, CA) was added to each well and and the plates
were incubated for an additional hour at 37°C. Excess
SA-HRP was removed by washing the wells three times and
then 50 l of TMB membrane peroxidase substrate (Kirke-
gaard & Perry Laboratories, Gaithersburg, MD) was added
to each well. Hydrolysis of this compound results in the
development of blue spots whose size and intensity are
directly proportional to the amount of bound IFN. (Zuck-
ermann et al., 1999). The frequency of virus-specific IFN-
-SC was determined by enumerating the blue spots.
As negative controls, 5  105 PBMCs per well were
either untreated or incubated with the reciprocal virus (PR
or PRRS virus) to which the pig had not been exposed. In all
cases the background did not exceed five spots per well and
the obtained values were subtracted from the respective
counts obtained from the stimulated cells. To confirm the
ability of each PBMC sample to produce IFN, 5  104
PBMCs per well were cultured in the presence of 10 g/ml
of the mitogen phytohemagglutinin. In all instances a pos-
itive response was observed.
Phenotyping of IFN--secreting cells
PBMCs were obtained from pigs which had been vacci-
nated twice at a 3-week interval with RespPRRS MLV 5
months earlier. A 1-ml volume of RPMI medium containing
2.5  106 cells was either incubated in the presence of a
saturating concentration of one of five (CD3, CD4, CD8,
CD8, CD21) anti-porcine CD mAbs or left untreated.
After 1 h at 4°C, 1 ml of rabbit complement (HLA-ABC/DR
Typing grade; Pel-Freeze, Brown Deer, WI) diluted 1:12 in
RPMI medium was added to each tube. After an additional
hour at 37°C, the cells were washed twice with PBS and
suspended in 1 ml of RPMI medium. One hundred micro-
liters of each cell preparation was then plated in triplicate
mAb P2G10-coated wells in a 96-well plate and exposed to
PRRS virus. After 20 h, the PBMCs were removed by
washing and the bottom surface of each well was tested for
IFN- deposition using the ELISPOT assay.
Acknowledgments
This study was supported by grants from the National
Pork Board, the USDA Animal Health and Disease program
and USDA NRI Program Grant No. 99-35204-0841. We
gratefully acknowledge Drs. Elizabeth Greeley and Joan
Lunney for helpful suggestion for preparation of the manu-
script.
References
Albina, E., Carrat, C., Charley, B, 1998a. Interferon-alpha response to
swine arterivirus (PoAV), the porcine reproductive and respiratory
syndrome virus. J. Interferon Cytokine Res. 18, 485–490.
Albina, E., Piriou, L., Hutet, E., Cariolet, R., L’Hospitalier, R, 1998b.
Immune responses in pigs infected with porcine reproductive and
respiratory syndrome virus (PRRSV). Vet. Immunol. Immunopathol.
61, 49–66.
Allende, R., Laegreid, W.W., Kutish, G.F., Galeota, J.A., Wills, R.W.,
Osorio, F.A, 2000. Porcine reproductive and respiratory syndrome
29W.A. Meier et al. / Virology 309 (2003) 18–31
virus: description of persistence in individual pigs upon experimental
infection. J. Virol. 74, 10834–10837.
Bahnemann, H.G, 1975. Binary ethylenimine as an inactivant for foot-and-
mouth disease virus and its application for vaccine production. Arch.
Virol. 47, 47–56.
Banchereau, J., Steinman, R.M, 1998. Dendritic cells and the control of
immunity. Nature 392, 245–252.
Bautista, E.M., Molitor, T.W, 1997. Cell-mediated immunity to porcine
reproductive and respiratory syndrome virus in swine. Viral Immunol.
10, 83–94.
Bautista, E.M., Molitor, T.W, 1999. IFN gamma inhibits porcine repro-
ductive and respiratory syndrome virus replication in macrophages.
Arch. Virol. 144, 1191–1200.
Bautista, E.M., Suarez, P., Molitor, T.W, 1999. T cell responses to the
structural polypeptides of porcine reproductive and respiratory syn-
drome virus. Arch. Virol. 144, 117–134.
Benfield, D.A., Nelson, E., Collins, J.E., Harris, L., Goyal, S.M., Robison,
D., Christianson, W.T., Morrison, R.B., Gorcyca, D., Chladek, D,
1992. Characterization of swine infertility and respiratory syndrome
(SIRS) virus (isolate ATCC VR-2332). J. Vet. Diagn. Invest. 4, 127–
133.
Buddaert, W., Van Reeth, K., Pensaert, M, 1998. In vivo and in vitro
interferon (IFN) studies with the porcine reproductive and respiratory
syndrome virus (PRRSV). Adv. Exp. Med. Biol. 440, 461–467.
Cavanagh, D, 1997. Nidovirales: a new order comprising Coronaviridae
and Arteriviridae. Arch. Virol. 142, 629–633.
Cella, M., Facchetti. F., Lanzavecchia, A., Colonna, M, 2000. Plasmacy-
toid dendritic cells activated by influenza virus and CD40L drive a
potent TH1 polarization. Nat. Immunol. 1, 305–310.
Collins, J.E., Benfield, D.A., Christianson, W.T., Harris, L., Hennings,
J.C., Shaw, D.P., Goyal, S.M., McCullough, S., Morrison, R.B., Joo,
H.S., Gorcyca, D., Chladek, D, 1992. Isolation of swine infertility and
respiratory syndrome virus (isolate ATCC VR-2332) in North America
and experimental reproduction of the disease in gnotobiotic pigs. J. Vet.
Diagn. Invest. 4, 117–126.
Conzelmann, K.K., Visser, N., Van Woensel, P., Thiel, H.J, 1993. Molec-
ular characterization of porcine reproductive and respiratory syndrome
virus, a member of the arterivirus group. Virology 193, 329–339.
Cousens, L.P., Peterson, R., Hsu, S., Dorner, A., Altman, J.D., Ahmed, R.,
Biron, C.A, 1999. Two roads diverged: interferon alpha/beta- and
interleukin 12-mediated pathways in promoting T cell interferon
gamma responses during viral infection. J. Exp. Med. 189, 1315–1328.
Flan˜o, E., Woodland, D.L., Blackman, M.A., Doherty, P.C, 2001. Analysis
of virus-specific CD4() t cells during long-term gammaherpesvirus
infection. J. Virol. 75, 7744–7748.
Foss, D.L., Zilliox, M.J., Meier, W., Zuckerman, F., Murtaugh, M.P., 2002.
Adjuvant danger signals increase the immune response to porcine
reproductive and respiratory syndrome virus. Viral Immunol. 15, 557–
566.
Fust, G, 1997. Enhancing antibodies in HIV infection. Parasitology 115,
127–140.
Gonin, P., Pirzadeh, B., Gagnon, C.A., Dea, S, 1999. Seroneutralization of
porcine reproductive and respiratory syndrome virus correlates with
antibody response to the GP5 major envelope glycoprotein. J. Vet.
Diagn. Invest. 11, 20–26.
Ho, D.D., McKeating, J.A., Li, X.L., Moudgil, T., Daar, E.S., Sun, N.C.,
Robinson, J.E, 1991. Conformational epitope on gp120 important in
CD4 binding and human immunodeficiency virus type 1 neutralization
identified by a human monoclonal antibody. J. Virol. 65, 489–493.
Homann, D., Teyton, L., Oldstone, M.B, 2001. Differential regulation of
antiviral T-cell immunity results in stable CD8 but declining CD4
T-cell memory. Nat. Med. 7, 913–919.
Kadowaki, N., Antonenko, S., Lau, J.Y., Liu, Y.J, 2000. Natural interferon
alpha/beta-producing cells link innate and adaptive immunity. J. Exp.
Med. 192, 219–226.
Kim, H.S., Kwang, J., Yoon, I.J., Joo, H.S., Frey, M.L, 1993. Enhanced
replication of porcine reproductive and respiratory syndrome (PRRS)
virus in a homogeneous subpopulation of MA-104 cell line. Arch.
Virol. 133 (3–4), 477–483.
Labarque, G.G., Nauwynck, H.J., Van Reeth, K., Pensaert, M.B., 2000.
Effect of cellular changes and onset of humoral immunity on the
replication of porcine reproductive and respiratory syndrome virus in
the lungs of pigs. J. Gen. Virol. 81, 1327–1334.
Lager, K.M., Mengeling, W.L., Brockmeier, S.L, 1997. Duration of ho-
mologous porcine reproductive and respiratory syndrome virus immu-
nity in pregnant swine. Vet. Microbiol. 58, 127–133.
Larghi, O.P., Nebel, A.E, 1980. Rabies virus inactivation by binary ethyl-
enimine: new method for inactivated vaccine production. J. Clin. Mi-
crobiol. 11, 120–122.
Lighvani, A.A., Frucht, D.M., Jankovic, D., Yamane, H., Aliberti, J.,
Hissong, B.D., Nguyen, B.V., Gadina, M., Sher, A., Paul, W.E.,
O’Shea, J.J, 2001. T-bet is rapidly induced by interferon-gamma in
lymphoid and myeloid cells. Proc. Natl. Acad. Sci. USA 98, 15137–
15142.
Loemba, H.D., Mounir, S., Mardassi, H., Archambault, D., Dea, S, 1996.
Kinetics of humoral immune response to the major structural proteins
of the porcine reproductive and respiratory syndrome virus. Arch.
Virol. 141, 751–761.
Lopez-Fuertes, L., Domenech, N., Alvarez, B., Ezquerra, A., Dominguez,
J., Castro, J.M., Alonso, F, 1999. Analysis of cellular immune response
in pigs recovered from porcine respiratory and reproductive syndrome
infection. Virus Res. 64, 33–42.
Mateu de Antonio, E., Husmann, R.J., Hansen, R., Lunney, J.K., Strom, D.,
Martin, S., Zuckermann, F.A, 1998. Quantitative detection of porcine
interferon-gamma in response to mitogen, superantigen and recall viral
antigen. Vet. Immunol. Immunopathol. 61, 265–277.
Mengeling, W.L., Lager, K.M., Vorwald, A.C, 1995. Diagnosis of porcine
reproductive and respiratory syndrome. J. Vet. Diagn. Invest. 7, 3–16.
Mengeling, W.L., Lager, K.M., Vorwald, A.C, 1999. Safety and efficacy of
vaccination of pregnant gilts against porcine reproductive and respira-
tory syndrome. Am. J. Vet. Res. 60, 796–801.
Mengeling, W.L., Vorwald, A.C., Lager, K.M., Brockmeier, S.L, 1996.
Diagnosis of porcine reproductive and respiratory syndrome using
infected alveolar macrophages collected from live pigs [published
erratum appears in Vet. Microbiol. 52, 317]. Vet. Microbiol. 49, 105–
115.
Meulenberg, J.J., Hulst, M.M., de Meuer, E.J, 1993. Lelystad virus, the
causative agent of porcine epidemic abortion and respiratory syndrome
(PEARS), is related to LDV and EAV. Virology 192, 62–72.
Molitor, T.W., Bautista, E.M., Choi, C.S, 1997. Immunity to PRRS virus:
double edge sword. Vet. Microbiol. 55, 265–276.
Murtaugh, M.P., Xiao, Z., Zuckermann, F.A., 2002. Immunological re-
sponses of swine to porcine reproductive and respiratory syndrome
virus infection. Viral Immunol. 15, 533–547.
Nam, K., Akari, H., Terao, K., Shibata, H., Kawamura, S., Yoshikawa, Y,
2000. Peripheral blood extrathymic CD4()CD8() T cells with high
cytotoxic activity are from the same lineage as CD4()CD8() T cells
in cynomolgus monkeys. Int. Immunol. 12, 1095–1103.
Nelson, E.A., Christopher-Hennings, J., Benfield, D.A, 1994. Serum im-
mune responses to the proteins of porcine reproductive and respiratory
syndrome (PRRS) virus. J. Vet. Diagn. Invest. 6, 410–415.
Ober, B.T., Summerfield, A., Mattlinger, C., Wiesmuller, K.H., Jung, G.,
Pfaff, E., Saalmuller, A., Rziha, H.J, 1998. Vaccine-induced, pseudo-
rabies virus-specific, extrathymic CD4CD8 memory T-helper cells
in swine. J. Virol. 72, 4866–4873.
Orme, I.M., Andersen, P., Boom, W.H, 1993. T cell response to Myco-
bacterium tuberculosis. J. Infect. Dis. 167, 1481–1497.
Orme, I.M., Miller, E.S., Roberts, A.D., Furney, S.K., Griffin, J.P., Dobos,
K.M., Chi, D., Rivoire, B., Brennan, P.J, 1992. T lymphocytes medi-
ating protection and cellular cytolysis during the course of Mycobac-
terium tuberculosis infection. Evidence for different kinetics and rec-
ognition of a wide spectrum of protein antigens. J. Immunol. 148,
189–196.
30 W.A. Meier et al. / Virology 309 (2003) 18–31
Osorio, F.A., Galeota, J.A., Nelson, E., Brodersen, B., Doster, A., Will, R.,
Zuckermann, F.A., Laegreid, W.W., 2002. Passive transfer of virus-
specific neutralizing antibodies confers protection against reproductive
failure induced by a virulent strain of porcine reproductive and respi-
ratory syndrome virus and establishes sterilizing immunity. Virology
302, 9–26.
Ostrowski, M., Galeota, J.A., Jar, A.M., Platt, K.B., Osorio, F.A., Lopez,
O.J, 2002. Identification of neutralizing and nonneutralizing epitopes in
the porcine reproductive and respiratory syndrome virus GP5 ectodo-
main. J. Virol. 76, 4241–4250.
Pilgrim, A.K., Pantaleo, G., Cohen, O.J., Fink, L.M., Zhou, J.Y., Zhou,
J.T., Bolognesi, D.P., Fauci, A.S., Montefiori, D.C, 1997. Neutralizing
antibody responses to human immunodeficiency virus type 1 in primary
infection and long-term-nonprogressive infection. J. Infect. Dis. 176,
924–932.
Pirzadeh, B., Dea, S, 1998. Immune response in pigs vaccinated with
plasmid DNA encoding ORF5 of porcine reproductive and respiratory
syndrome virus. J. Gen. Virol. 79, 989–999.
Plagemann, P.G.W., Moennig, V, 1992. Lactate dehydrogenase-elevating
virus, equine arteritis virus, and simian hemorrhagic fever virus: a new
group of positive-strand RNA viruses. Adv. Virus. Res. 41, 99–192.
Pol, J., Wagenaar, F, 1992. Morphogenesis of Lelystad virus in porcine
alveolar macrophages. Am. Assoc. Swine Pract. Newslett. 4, 29.
Pringle, C.R, 1996. Virus taxonomy 1996—a bulletin from the Xth Inter-
national Congress of Virology in Jerusalem. Arch. Virol. 141, 2251–
2256.
Ramsay, A.J., Ruby, J., Ramshaw, I.A, 1993. A case for cytokines as
effector molecules in the resolution of virus infection. Immunol. Today
14, 155–157.
Reed, I.J., Muench, R.H, 1938. A simple method of estimating fifty percent
end points. Am. J. Hyg. 27, 493–497.
Rentenaar, R.J., Gamadia, L.E., van DerHoek, N., van Diepen, F.N.,
Boom, R., Weel, J.F., Wertheim-van Dillen, P.M., van Lier, R.A., ten
Berge, I.J, 2000. Development of virus-specific CD4() T cells during
primary cytomegalovirus infection. J. Clin. Invest. 105, 541–548.
Rodriguez-Carreno, M.P., Lopez-Fuertes, L., Revilla, C., Ezquerra, A.,
Alonso, F., Dominguez, J, 2002. Phenotypic characterization of porcine
IFN-gamma-producing lymphocytes by flow cytometry. J. Immunol.
Methods 259, 171–179.
Rossow, K.D., Collins, J.E., Goyal, S.M., Nelson, E.A., Christopher-
Hennings, J., Benfield, D.A, 1995. Pathogenesis of porcine reproduc-
tive and respiratory syndrome virus infection in gnotobiotic pigs. Vet.
Pathol. 32, 361–373.
Rowland, R.R., Robinson, B., Stefanick, J., Kim, T.S., Guanghua, L.,
Lawson, S.R., Benfield, D.A, 2001. Inhibition of porcine reproductive
and respiratory syndrome virus by interferon-gamma and recovery of
virus replication with 2-aminopurine. Arch. Virol. 146, 539–555.
Sallusto, F., Lenig, D., Forster, R., Lipp, M., Lanzavecchia, A., 1999. Two
subsets of memory T lymphocytes with distinct homing potentials and
effector functions. Nature 401, 708–712.
Shibata, I., Mori, M., Uruno, K., Samegai, Y., Okada, M, 1997. In vivo
replication of porcine reproductive and respiratory syndrome virus in
swine alveolar macrophages and change in the cell population in
bronchoalveolar lavage fluid after infection. J. Vet. Med. Sci. 59,
539–543.
Shibata, I., Mori, M., Yazawa, S, 2000. Experimental reinfection with
homologous porcine reproductive and respiratory syndrome virus in
SPF pigs. J. Vet. Med. Sci. 62, 105–108.
Steinman, R.M, 1991. The dendritic cell system and its role in immuno-
genicity. Annu. Rev. Immunol. 9, 271–296.
Summerfield, A., Rziha, H.J., Saalmuller, A, 1996. Functional character-
ization of porcine CD4CD8 extrathymic T lymphocytes. Cell Im-
munol. 168, 291–296.
Sur, J.H., Doster, A.R., Christian, J.S., Galeota, J.A., Wills, R.W., Zim-
merman, J.J., Osorio, F.A, 1997. Porcine reproductive and respiratory
syndrome virus replicates in testicular germ cells, alters spermatogen-
esis, and induces germ cell death by apoptosis. J. Virol. 71, 9170–9179.
Topham, D.J., Doherty, P.C, 1998. Longitudinal analysis of the acute
Sendai virus-specific CD4 T cell response and memory. J. Immunol.
161, 4530–4535.
Van Reeth, K, 1997. Pathogenesis and clinical aspects of a respiratory
porcine reproductive and respiratory syndrome virus infection. Vet.
Microbiol. 55, 223–230.
Van Reeth, K., Labarque, G., Nauwynck, H., Pensaert, M, 1999. Differ-
ential production of proinflammatory cytokines in the pig lung during
different respiratory virus infections: correlations with pathogenicity.
Res. Vet. Sci. 67, 47–52.
van Woensel, P.A., Liefkens, K., Demaret, S, 1998. Effect on viraemia of
an American and a European serotype PRRSV vaccine after challenge
with European wild-type strains of the virus. Vet. Rec. 142, 510–512.
Vezina, S.A., Loemba, H., Fournier, M., Dea, S., Archambault, D, 1996.
Antibody production and blastogenic response in pigs experimentally
infected with porcine reproductive and respiratory syndrome virus.
Can. J. Vet. Res. 60, 94–99.
Voicu, I.L., Silim, A., Morin, M., Elazhary, M.A, 1994. Interaction of
porcine reproductive and respiratory syndrome virus with swine mono-
cytes. Vet. Rec. 134, 422–423.
Waldrop, S.L., Pitcher, C.J., Peterson, D.M., Maino, V.C., Picker, L.J,
1997. Determination of antigen-specific memory/effector CD4 T cell
frequencies by flow cytometry: evidence for a novel, antigen-specific
homeostatic mechanism in HIV-associated immunodeficiency. J. Clin.
Invest. 99, 1739–1750.
Wensvoort, G, 1993. Lelystad virus and the porcine epidemic abortion and
respiratory syndrome. Vet. Res. 24, 117–124.
Wensvoort, G., Terpstra, C., Pol, J.M.A, 1991. Mystery swine disease in
The Netherlands: the isolation of Lelystad virus. Vet. Q. 13, 121–130.
Wills, R.W., Zimmerman, J.J., Yoon, K.J., Swenson, S.L., McGinley, M.J.,
Hill, H.T., Platt, K.B., Christopher-Hennings, J., Nelson, E.A, 1997.
Porcine reproductive and respiratory syndrome virus: a persistent in-
fection. Vet. Microbiol. 55, 231–240.
Wu, W.H., Fang, Y., Farwell, R., Steffen-Bien, M., Rowland, R.R., Chris-
topher-Hennings, J., Nelson, E.A, 2001. A 10-kDa structural protein of
porcine reproductive and respiratory syndrome virus encoded by
ORF2b. Virology 287, 183–191.
Yoon, K.J., Wu, L.L., Zimmerman, J.J., Hill, H.T., Platt, K.B, 1996.
Antibody-dependent enhancement (ADE) of porcine reproductive and
respiratory syndrome virus (PRRSV) infection in pigs. Viral Immunol.
9, 51–63.
Yoon, K.J., Zimmerman, J.J., Swenson, S.L., McGinley, M.J., Eernisse,
K.A., Brevik, A., Rhinehart, L.L., Frey, M.L., Hill, H.T., Platt, K.B,
1995. Characterization of the humoral immune response to porcine
reproductive and respiratory syndrome (PRRS) virus infection. J. Vet.
Diagn. Invest. 7, 305–312.
Zinkernagel, R.M., Bachmann, M.F., Kundig, T.M., Oehen, S., Pirchet, H.,
Hengartner, H, 1996. On immunological memory. Annu. Rev. Immu-
nol. 14, 333–367.
Zuckermann, F.A, 1999. Extrathymic CD4/CD8 double positive T cells.
Vet. Immunol. Immunopathol. 72, 55–66.
Zuckermann, F.A, 2000. Aujeszky’s disease virus: opportunities and chal-
lenges. Vet. Res. 31, 121–131.
Zuckermann, F.A., Husmann, R.J, 1996. Functional and phenotypic anal-
ysis of porcine peripheral blood CD4/CD8 double-positive T cells.
Immunology 87, 500–512.
Zuckermann, F.A., Husmann, R.J., Schwartz, R., Brandt, J., Mateu de
Antonio, E., Martin, S, 1998. Interleukin-12 enhances the virus-specific
interferon gamma response of pigs to an inactivated pseudorabies virus
vaccine. Vet. Immunol. Immunopathol. 63, 57–67.
Zuckermann, F.A., Martin, S., Husmann, R.J., Brandt, J, 1999. Use of
interleukin 12 to enhance the cellular immune response of swine to an
inactivated herpesvirus vaccine. Adv. Vet. Med. 41, 447–461.
Zuckermann, F.A., Zsak, L., Mettenleiter, T.C., Ben-Porat, T, 1990. Pseu-
dorabies virus glycoprotein gIII is a major target antigen for murine and
swine virus-specific cytotoxic T lymphocytes. J. Virol. 64, 802–812.
31W.A. Meier et al. / Virology 309 (2003) 18–31
